Clinical trials: Coronary Vessel
Varicose Veins
Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt
The purpose of this study is to determine the safety of the Varisolve® procedure in patients with right-to-left cardiac shunt (a defect in the heart).
- Trial name
- MRI (NCT00442364)
- Testing
- Polidocanol (1%) Microfoam (Varisolve), Endovenous Microfoam Occlusion
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Participants being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study.
- Trial name
- GadaCAD 1 (NCT01890421)
- Testing
- Gadobutrol (Gadovist, Gadavist, BAY86-4875)
- Where
- 23 sites in United States, France and 5 more
- Volunteers
- 426 people
- Sponsor
- Bayer
Stable Coronary Artery Disease (CAD), Myocardial Infarction
Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients
THis study is intended to provide contemporary data on the burden of disease in patients 1 to 3 years post-MI, including a description of patient characteristics, current treatment patterns, rate of major CV events, and…
- Trial name
- TIGRIS (NCT01866904)
- Where
- 309 sites in United States, Argentina and 23 more
- Volunteers
- 9,284 people
- Sponsor
- AstraZeneca
Heart Failure, Arterial Hypertension
Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD
1. To measure the ability of trans-resveratrol to influence the development of chronic heart failure (CHF) in women in the early postmenopausal period (1-4 years) with hypertension (HTN) and reduced bone mineral density (BMD). 2.
- Conditions
- Heart Failure, Arterial Hypertension, Osteopenia, Menopause
- Trial name
- Not aplicable (NCT06828211)
- Testing
- Trans-resveratrol extract from Polygonum Cuspidatum
- Where
- Ukraine
- Volunteers
- 80 people
- Sponsor
- OMNIFARMA LLC
Coronary Artery Disease, Coronary Artery Stenosis
To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
The study will evaluate the performance and safety of RisoR Crest Everolimus Eluting Coronary Stent System. A total of 2000 participants will be included in the study from India and Italy.
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Percutaneous Coronary Intervention, de Novo Lesions in Native Coronary Arteries
- Trial name
- PACIFIER (NCT07098195)
- Testing
- Coronary Stent
- Volunteers
- 2,000 people
- Sponsor
- Poly Medicure Limited
Severe Coronary Artery Disease (S-CAD)
SPIROCOR Coronary Outcome by Respiratory Stress Examination
The purpose of this study is to validate the accuracy of the SPIROCOR System in indicating the presence of significant coronary artery disease (S-CAD), as defined in ACC/AHA Guidelines, in subjects with suspected S-CAD.
- Trial name
- SCORE (NCT01053975)
- Where
- 29 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Spirocor
In-Stent Restenosis, Cardiovascular Diseases
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis.
- Conditions
- In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
- Trial name
- MAGICAL ISR (NCT05908331)
- Testing
- Sirolimus Drug Coated Balloon, Plan balloon Angioplasty (POBA)
- Where
- 28 sites in United States
- Volunteers
- 492 people
- Sponsor
- Concept Medical Inc.
Cardiac Surgery, Coronary Artery Bypass
An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery
This study investigates the effect of two dose-levels of AP214 on the prevention of (acute) kidney injury after cardiac surgery.
- Conditions
- Cardiac Surgery, Coronary Artery Bypass, Aortic Aneurysm, Valve Surgery
- Trial name
- NCT01256372
- Testing
- AP214
- Where
- Denmark
- Volunteers
- 77 people
- Sponsor
- Action Pharma A/S
Coronary Artery Disease
Medtronic Resolute Onyx 2.0 mm Clinical Study
The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries that allows the use of a 2.0 mm…
- Trial name
- NCT02412501
- Testing
- Resolute Onyx Stent - 2.0 mm
- Where
- 17 sites in United States
- Volunteers
- 101 people
- Sponsor
- Medtronic Vascular
Type2 Diabetes, Antiplatelet Drugs
Type 2 Diabetes With Antiplatelet Drugs
Tabula Rasa HealthCare (TRHC), d/b/a CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services.
- Conditions
- Type2 Diabetes, Antiplatelet Drugs, Myocardial Infarction, Heart Failure
- Trial name
- NCT05053828
- Testing
- Antiplatelet Drug
- Where
- United States
- Volunteers
- 173,464 people
- Sponsor
- Tabula Rasa HealthCare
Hypertension and Chronic Heart Failure
Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses
- Trial name
- NCT02151994
- Testing
- BIA 5-1058
- Where
- Netherlands
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Coronary Artery Disease
The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by…
- Trial name
- NCT01665053
- Testing
- PROMUS Element Plus, SYNERGY
- Where
- 126 sites in United States, Australia and 14 more
- Volunteers
- 1,684 people
- Sponsor
- Boston Scientific Corporation
Ischemic Heart Disease
Autologous Cell Therapy for Ischemic Heart Failure
The aim of this clinical study is to investigate the safety and feasibility of Autologous Muscle-derived Cells (AMDC; a preparation of a patient's own cells) as a treatment for patients with advanced heart failure caused by…
- Trial name
- NCT01353690
- Testing
- AMDC
- Where
- 2 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Cook MyoSite
Coronary Artery Disease
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body.
- Trial name
- NCT00335335
- Testing
- iodixanol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- GE Healthcare
Myocardial Infarction, Heart Failure, Congestive
Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter = SEISMIC Trial
To assess the efficacy and safety of MyoCell therapy on myocardial function in congestive heart failure patients, post-myocardial infarction
- Trial name
- NCT00375817
- Testing
- Myoblasts injection with MyoCath catheter
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bioheart, Inc.
Coronary Heart Disease
Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety
- Trial name
- NCT00134940
- Where
- 6 sites in Austria, Germany
- Volunteers
- 100 people
- Sponsor
- Novartis
STEMI
Efficacy and Safety on Prouk for STEMI Patients in China
The purpose of the study is to evaluate the efficacy and safety of rh-prouk as pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed as a multicenter, active controlled, single blinded…
- Trial name
- NCT02367976
- Testing
- rhprouk
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Suzhou RxD Biopharmaceutical Co., Ltd
Hypotension of Hemodialysis, Hypotension
Measuring Cardiovascular Stress in Patients on Hemodialysis Study II
The overall goal is to evaluate the predictive accuracy of a measure of autoregulatory adequacy derived from CVInsight and compare it with other measures in recognizing hypotensive events during hemodialysis..
- Conditions
- Hypotension of Hemodialysis, Hypotension, Estimated Dry Weight, Myocardial Injury
- Trial name
- NCT02182089
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Intelomed, Inc.
Coronary Restenosis
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following…
- Trial name
- SNAPIST-III (NCT00124943)
- Testing
- Nanoparticle Paclitaxel
- Volunteers
- 112 people
- Sponsor
- Celgene Corporation
Coronary Artery Stenosis
De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions
The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-metal stenting (BMS).
- Trial name
- NCT00934752
- Testing
- Lutonix Paclitaxel-Coated Balloon
- Where
- 3 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- C. R. Bard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.